Fate Therapeutics Inc
NASDAQ:FATE
Fate Therapeutics Inc
NASDAQ:FATE
Price:
3.8 USD
-1.81%
Market Closed
Updated:
Apr 29, 2024
Fate Therapeutics Inc
Cash from Investing Activities
|
Fate Therapeutics Inc
Cash from Investing Activities Peer Comparison
Comparables:
ABBV
GILD
AMGN
VRTX
REGN
Competitive Cash from Investing Activities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash from Investing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Fate Therapeutics Inc
NASDAQ:FATE
|
Cash from Investing Activities
$112.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Cash from Investing Activities
-$2B
|
CAGR 3-Years
62%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
N/A
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cash from Investing Activities
-$2.3B
|
CAGR 3-Years
46%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-24%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Cash from Investing Activities
-$26.2B
|
CAGR 3-Years
-69%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-12%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cash from Investing Activities
-$3.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-73%
|
CAGR 10-Years
-50%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cash from Investing Activities
-$3.2B
|
CAGR 3-Years
-256%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
-25%
|
See Also
What is Fate Therapeutics Inc's Cash from Investing Activities?
Cash from Investing Activities
112.7m
USD
112.7m
USD
Based on the financial report for Dec 31, 2023, Fate Therapeutics Inc's Cash from Investing Activities amounts to 112.7m USD.
What is Fate Therapeutics Inc's Cash from Investing Activities growth rate?
Cash from Investing Activities CAGR 1Y
-32%
-32%
Over the last year, the Cash from Investing Activities growth was -32%.
You don't have any saved screeners yet
